Fisher syndrome: clinical features, immunopathogenesis and management

References

• Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N. Engl. J. Med.255(2), 57–65 (1956).
   PubMed Web of Science ®Google Scholar
• Smith JL, Walsh FB. Syndrome of external ophthalmoplegia, ataxia, and areflexia (Fisher); ocular manifestations in acute idiopathic polyneuritis (Guillain–Barré syndrome); report of two cases. AMA Arch. Ophthalmol.58(1), 109–114 (1957).
   PubMedGoogle Scholar
• Goodwin RF, Poser CM. Ophthalmoplegia, ataxia, and areflexia. Fisher’s syndrome. JAMA186(3), 258–259 (1963).
   PubMed Web of Science ®Google Scholar
• Patel A, Pearce L, Hairston R. Miller Fisher Syndrome (variant of Landry–Guillain–Barré–Strohl syndrome – ophthalmoplegia, ataxia, areflexia). South. Med. J.59(2), 171–175 (1966).
   PubMed Web of Science ®Google Scholar
• Sauron B, Bouche P, Cathala HP, Chain F, Castaigne P. Miller Fisher syndrome: clinical and electrophysiologic evidence of peripheral origin in 10 cases. Neurology34(7), 953–956 (1984).
   PubMed Web of Science ®Google Scholar
• Berlit P, Rakicky J. The Miller Fisher syndrome. Review of the literature. J. Clin. Neuroophthalmol.12(1), 57–63 (1992).
   PubMedGoogle Scholar
• Al-Din SN, Anderson M, Eeg-Olofsson O, Trontelj JV. Neuro-ophthalmic manifestations of the syndrome of ophthalmoplegia, ataxia and areflexia: a review. Acta. Neurol. Scand.89(3), 157–163 (1994).
   PubMedGoogle Scholar
• Lyu RK, Tang LM, Cheng SY et al. Guillain–Barré syndrome in Taiwan: a clinical study of 167 patients. J. Neurol. Neurosurg. Psychiatry63(4), 494–500 (1997).
   PubMed Web of Science ®Google Scholar
• Yuan CL, Wang YJ, Tsai CP. Miller fisher syndrome: a hospital-based retrospective study. Eur. Neurol.44(2), 79–85 (2000).
   PubMed Web of Science ®Google Scholar
• Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology56(8), 1104–1106 (2001).
   PubMed Web of Science ®Google Scholar
• Lolekha P, Phanthumchinda K. Miller-Fisher syndrome at King Chulalongkorn Memorial Hospital. J. Med. Assoc. Thai.92(4), 471–477 (2009).
   PubMedGoogle Scholar
• San-Juan OD, Martinez-Herrera JF, Garcia JM et al. Miller Fisher syndrome: 10 years’ experience in a third-level center. Eur. Neurol.62(3), 149–154 (2009).
   PubMed Web of Science ®Google Scholar
• Koga M, Gilbert M, Li J et al. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology64(9), 1605–1611 (2005).
   PubMed Web of Science ®Google Scholar
• Kuitwaard K, van Koningsveld R, Ruts L, Jacobs BC, van Doorn PA. Recurrent Guillain–Barré syndrome. J. Neurol. Neurosurg. Psychiatry80(1), 56–59 (2009).
   PubMed Web of Science ®Google Scholar
• Nishimoto Y, Odaka M, Hirata K, Yuki N. Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J. Neuroimmunol.148(1), 200–205 (2004).
   PubMed Web of Science ®Google Scholar
• Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann. Neurol.31(6), 677–679 (1992).
   PubMed Web of Science ®Google Scholar
• Willison HJ, Veitch J, Paterson G, Kennedy PG. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J. Neurol. Neurosurg. Psychiatry56(2), 204–206 (1993).
   PubMed Web of Science ®Google Scholar
• Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of anti-GQ1b antibody in Fisher’s syndrome. Neurology43(2), 414–417 (1993).
   PubMed Web of Science ®Google Scholar
• Odaka M, Yuki N, Hirata K. Anti-GQ1b antibody syndrome: clinical and immunological range. J. Neurol. Neurosurg. Psychiatry70(1), 50–55 (2001).
   PubMed Web of Science ®Google Scholar
• Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain–Barré syndrome: clinical and immunohistochemical studies. Neurology43(10), 1911–1917 (1993).
   PubMed Web of Science ®Google Scholar
• Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology40(12), 1900–1902 (1990).
   PubMed Web of Science ®Google Scholar
• Yuki N, Susuki K, Koga M et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain–Barré syndrome. Proc. Natl Acad. Sci. USA101(31), 11404–11409 (2004).
   PubMed Web of Science ®Google Scholar
• Kohler A, de Torrenté A, Inderwildi B. Fisher’s syndrome associated with Campylobacter jejuni infection. Eur. Neurol.28(3), 150–151 (1988).
   PubMed Web of Science ®Google Scholar
• Yuki N, Ichikawa H, Doi A. Fisher syndrome after Campylobacter jejuni enteritis: human leukocyte antigen and the bacterial serotype. J. Pediatr.126(1), 55–57 (1995).
   PubMed Web of Science ®Google Scholar
• Yuki N, Taki T, Takahashi M et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher’s syndrome. Ann. Neurol.36(5), 791–793 (1994).
   PubMed Web of Science ®Google Scholar
• Jacobs BC, Endtz H, van der Meche FG, Hazenberg MP, Achtereekte HA, van Doorn PA. Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann. Neurol.37(2), 260–264 (1995).
   PubMed Web of Science ®Google Scholar
• Kimoto K, Koga M, Odaka M et al. Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology67(10), 1837–1843 (2006).
   PubMed Web of Science ®Google Scholar
• Kaida K, Kanzaki M, Morita D et al. Anti-ganglioside complex antibodies in Miller Fisher syndrome. J. Neurol. Neurosurg. Psychiatry77(9), 1043–1046 (2006).
   PubMed Web of Science ®Google Scholar
• Kanzaki M, Kaida K, Ueda M et al. Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain–Barre syndromes. J. Neurol. Neurosurg. Psychiatry79(10), 1148–1152 (2008).
   PubMed Web of Science ®Google Scholar
• Houliston RS, Koga M, Li J et al. A Haemophilus influenzae strain associated with Fisher syndrome expresses a novel disialylated ganglioside mimic. Biochemistry46(27), 8164–8171 (2007).
   PubMed Web of Science ®Google Scholar
• Funakoshi K, Kuwabara S, Odaka M, Hirata K, Yuki N. Clinical predictors of mechanical ventilation in Fisher/Guillain–Barré overlap syndrome. J. Neurol. Neurosurg. Psychiatry80(1), 60–64 (2009).
   PubMed Web of Science ®Google Scholar
• van der Meche FG, van Doorn PA, Meulstee J, Jennekens FG, GBS-consensus group of the Dutch Neuromuscular Research Support Centre. Diagnostic and classification criteria for the Guillain–Barré syndrome. Eur. Neurol.45(3), 133–139 (2001).
   PubMed Web of Science ®Google Scholar
• Yuki N. Acute paresis of extraocular muscles associated with IgG anti-GQ1b antibody. Ann. Neurol.39(5), 668–672 (1996).
   PubMed Web of Science ®Google Scholar
• Yuki N, Odaka M, Hirata K. Acute ophthalmoparesis (without ataxia) associated with anti-GQ1b IgG antibody: clinical features. Ophthalmology108(1), 196–200 (2001).
   PubMed Web of Science ®Google Scholar
• Lee SH, Lim GH, Kim JS et al. Acute ophthalmoplegia (without ataxia) associated with anti-GQ1b antibody. Neurology71(6), 426–429 (2008).
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Mannen T, Kusunoki S. Acute isolated ophthalmoplegia as a variant of Miller-Fisher syndrome. Muscle Nerve21(8), 1107 (1998).
   PubMedGoogle Scholar
• Mori M, Kuwabara S, Koga M et al. IgG anti-GQ1b positive acute ataxia without ophthalmoplegia. J. Neurol. Neurosurg. Psychiatry67(5), 668–670 (1999).
   PubMed Web of Science ®Google Scholar
• Kusunoki S, Chiba A, Kanazawa I. Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve22(8), 1071–1074 (1999).
   PubMed Web of Science ®Google Scholar
• Yuki N, Susuki K, Hirata K. Ataxic Guillain–Barré syndrome with anti-GQ1b antibody: relation to Miller Fisher syndrome. Neurology54(9), 1851–1853 (2000).
   PubMed Web of Science ®Google Scholar
• Ito M, Matsuno K, Sakumoto Y, Hirata K, Yuki N. Ataxic Guillain–Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J. Neurol. Neurosurg. Psychiatry82(3), 294–299 (2011).
   PubMed Web of Science ®Google Scholar
• Yuki N, Koga M, Hirata K. Isolated internal ophthalmoplegia associated with immunoglobulin G anti-GQ1b antibody. Neurology51(5), 1515–1516 (1998).
   PubMed Web of Science ®Google Scholar
• Ito M, Matsuno K, Sakumoto Y, Hirata K, Yuki N. Ataxic Guillain–Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J. Neurol. Neurosurg. Psychiatry82(3), 294–299 (2011).
   PubMed Web of Science ®Google Scholar
• Bickerstaff ER. Brainstem encephalitis. Br. Med. J.1(5032), 1384–1387 (1957).
   PubMed Web of Science ®Google Scholar
• Yuki N, Miyatani N, Sato S et al. Acute relapsing sensory neuropathy associated with IgM antibody against B-series gangliosides containing a GalNAc β1–4(Gal3–2 αNeuAc8–2αNeuAc) β1 configuration. Neurology42(3), 686–689 (1992).
   PubMed Web of Science ®Google Scholar
• Notturno F, Caporale CM, Uncini A. Acute sensory ataxic neuropathy with antibodies to GD1b and GQ1b gangliosides and prompt recovery. Muscle Nerve37(2), 265–268 (2008).
   PubMed Web of Science ®Google Scholar
• O’Leary CP, Veitch J, Durward WF, Thomas AM, Rees JH, Willison HJ. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J. Neurol. Neurosurg. Psychiatry61(6), 649–651 (1996).
   PubMed Web of Science ®Google Scholar
• Koga M, Yuki N, Ariga T, Morimatsu M, Hirata K. Is IgG anti-GT1a antibody associated with pharyngeal–cervical–brachial weakness or oropharyngeal palsy in Guillain–Barré syndrome? J. Neuroimmunol.86(1), 74–79 (1998).
   PubMed Web of Science ®Google Scholar
• Taly AB, Prasad A, Vasanth A, Shankar SK, Nagaraja D. Acute ataxic neuropathy: a clinical, electrophysiological and morphological study. Acta. Neurol. Scand.84(5), 398–402 (1991).
   PubMed Web of Science ®Google Scholar
• Susuki K, Yuki N, Hirata K. Fine specificity of anti-GQ1b IgG and clinical features. J. Neurol. Sci.185(1), 5–9 (2001).
   PubMed Web of Science ®Google Scholar
• Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Clinical correlates of serum anti-GT1a IgG antibodies. J. Neurol. Sci.219(1–2), 139–145 (2004).
   PubMed Web of Science ®Google Scholar
• Odaka M, Yuki N, Yamada M et al. Bickerstaff’s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain–Barré syndrome. Brain126(10), 2279–2290 (2003).
   PubMed Web of Science ®Google Scholar
• Ito M, Kuwabara S, Odaka M et al. Bickerstaff’s brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J. Neurol.255(5), 674–682 (2008)
   PubMed Web of Science ®Google Scholar
• Yuki N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher–Bickerstaff syndrome). J. Neuroimmunol.215(1–2), 1–9 (2009).
   PubMed Web of Science ®Google Scholar
• Ogawara K, Kuwabara S, Yuki N. Fisher syndrome or Bickerstaff brainstem encephalitis? Anti-GQ1b IgG antibody syndrome involving both the peripheral and central nervous systems. Muscle Nerve26(6), 845–849 (2002).
   PubMed Web of Science ®Google Scholar
• Koga M, Yuki N, Tai T, Hirata K. Miller Fisher syndrome and Haemophilus influenzae infection. Neurology57(4), 686–691 (2001).
   PubMed Web of Science ®Google Scholar
• Yuki N, Shahrizaila N. How do we identify infectious agents that trigger Guillain–Barré syndrome, Fisher syndrome and Bickerstaff brainstem encephalitis? J. Neurol. Sci.302(1–2), 1–5 (2011).
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Asahina M, Nakajima M et al. Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis. Ann. Neurol.45(4), 533–536 (1999).
   PubMed Web of Science ®Google Scholar
• Overell JR, Hsieh ST, Odaka M et al. Treatment for Fisher syndrome, Bickerstaff’s brainstem encephalitis and related disorders. Cochrane Database Syst. Rev.1, CD004761 (2007).
   Google Scholar
• Donofrio PD, Berger A, Brannagan TH III et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve40(5), 890–900 (2009).
   PubMed Web of Science ®Google Scholar
• Mori M, Kuwabara S. Fisher syndrome. Curr. Treat. Options Neurol.13(1), 71–78 (2011).
   PubMed Web of Science ®Google Scholar
• Guillain –Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain–Barré syndrome. Lancet341(8845), 586–590 (1993).
   PubMed Web of Science ®Google Scholar
• Mori M, Kuwabara S, Fukutake T, Hattori T. Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases. J. Neurol. Neurosurg. Psychiatry72(5), 680 (2002).
   PubMed Web of Science ®Google Scholar
• Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology68(14), 1144–1146 (2007).
   PubMed Web of Science ®Google Scholar
• Shimokawa M, Shinoda T, Takahashi M, Watabiki S. Successful plasmapheresis in the not-so-benign Bickerstaff’s brain stem encephalitis associated with anti-GQ1b antibody. Ther. Apher.2(3), 240–242 (1998).
   PubMedGoogle Scholar
• Fox RJ, Kasner SE, Galetta SL, Chalela JA. Treatment of Bickerstaff’s brainstem encephalitis with immune globulin. J. Neurol. Sci.178(2), 88–90 (2000).
   PubMed Web of Science ®Google Scholar
• van Koningsveld R, Schmitz PI, Meché FG et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain–Barré syndrome: randomised trial. Lancet363(9404), 192–196 (2004).
   PubMed Web of Science ®Google Scholar
• Halstead SK, Humphreys PD, Zitman FM, Hamer J, Plomp JJ, Willison HJ. C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome. J. Peripher. Nerv. Syst.13(3), 228–235 (2008).
   PubMed Web of Science ®Google Scholar
• Halstead SK, Zitman FM, Humphreys PD et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain131(5), 1197–1208 (2008).
   PubMed Web of Science ®Google Scholar
• Ricker K, Hertel G. Electrophysiological findings in the syndrome of acute ocular muscle palsy with ataxia (Fisher syndrome). J. Neurol.214(1), 35–44 (1976).
   PubMed Web of Science ®Google Scholar
• Czarnecki JS, Hachinski V. Site of lesion in Fisher syndrome. Ann. Neurol.4(2), 158–159 (1978).
   PubMedGoogle Scholar
• Nowack WJ, French MW, Gilmor R. Central nervous system lesions in Fisher syndrome: report of a case with CT findings. J. Indiana State Med. Assoc.75(9), 623–624 (1982).
   PubMedGoogle Scholar
• Phillips MS, Stewart S, Anderson JR. Neuropathological findings in Miller Fisher syndrome. J. Neurol. Neurosurg. Psychiatry47(5), 492–495 (1984).
   PubMed Web of Science ®Google Scholar
• Al-Din AN, Anderson M, Bickerstaff ER, Harvey I. Brainstem encephalitis and the syndrome of Miller Fisher. A clinical study. Brain105(3), 481–495 (1982).
   PubMed Web of Science ®Google Scholar
• Ropper AH, Shahani B. Proposed mechanism of ataxia in Fisher’s syndrome. Arch. Neurol.40(9), 397–398 (1983).
   PubMedGoogle Scholar
• Ropper A. Absence of CNS lesion in autopsied patients with Miller-Fisher syndrome. Arch. Neurol.42(1), 15 (1985).
   PubMedGoogle Scholar
• Al-Din AN. The nosological position of the ophthalmoplegia, ataxia, and areflexia syndrome: ‘the spectrum hypothesis’. Acta. Neurol. Scand.75(5), 287–294 (1987).
   PubMed Web of Science ®Google Scholar
• Derakhshan I. Guillain–Barré, Fisher, and Bickerstaff syndromes: nature versus well established ideas. J. Neurol. Neurosurg. Psychiatry69(5), 703–704 (2000).
   PubMedGoogle Scholar
• Taphoorn MJ, Lanting P, Hazenberg GJ, Uitdehaag BJ, Kaiser MC. Observations on the lesion site in the Miller Fisher syndrome: presentation of a case including CT and MRI. Acta. Neurol. Scand.80(2), 167–169 (1989).
   PubMed Web of Science ®Google Scholar
• Giroud M, Mousson C, Chalopin JM, Rifle G, Dumas R. Miller-Fisher syndrome and pontine abnormalities on MRI: a case report. J. Neurol.237(8), 489–490 (1990).
   PubMed Web of Science ®Google Scholar
• Liu JX, Willison HJ, Pedrosa-Domellöf F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest. Ophthalmol. Vis. Sci.50(7), 3226–3232 (2009).
   PubMed Web of Science ®Google Scholar
• Kornberg AJ, Pestronk A, Blume GM, Lopate G, Yue J, Hahn A. Selective staining of the cerebellar molecular layer by serum IgG in Miller-Fisher and related syndromes. Neurology47(5), 1317–1320 (1996).
   PubMed Web of Science ®Google Scholar
• Tuzün E, Kurtuncu M, Lang B et al. Bickerstaff’s encephalitis and Miller Fisher syndrome associated with voltage-gated potassium channel and novel anti-neuronal antibodies. Eur. J. Neurol.17(10), 1304–1307(2010).
   PubMed Web of Science ®Google Scholar
• Kim YK, Kim JS, Jeong SH, Park KS, Kim SE, Park SH. Cerebral glucose metabolism in Fisher syndrome. J. Neurol. Neurosurg. Psychiatry80(5), 512–517 (2009).
   PubMed Web of Science ®Google Scholar
• Nakatani Y, Murata M, Shibata K et al. IgM anti-GQ1b monoclonal antibody inhibits voltage-dependent calcium current in cerebellar granule cells. Exp. Neurol.219(1), 74–80 (2009).
   PubMed Web of Science ®Google Scholar
• Lo YL, Fook-Chong S, Chan LL, Ong WY, Ratnagopal P. Electrophysiological evidence of cerebellar fiber system involvement in the Miller Fisher syndrome. J. Neurol. Sci.288(1–2), 49–53 (2010).
   PubMed Web of Science ®Google Scholar
• Ohsawa T. Rat dorsal root ganglion gangliosides during early development until senescence. Mech. Ageing Dev.53(3), 259–266 (1990).
   PubMed Web of Science ®Google Scholar
• Ohsawa T, Miyatake T, Yuki N. Anti-B-series ganglioside-recognizing autoantibodies in an acute sensory neuropathy patient cause cell death of rat dorsal root ganglion neurons. Neurosci. Lett.157(2), 167–170 (1993).
   PubMed Web of Science ®Google Scholar
• Roberts M, Willison H, Vincent A, Newsom-Davis J. Serum factor in Miller-Fisher variant of Guillain–Barré syndrome and neurotransmitter release. Lancet343(8895), 454–455 (1994).
   PubMed Web of Science ®Google Scholar
• Buchwald B, Weishaupt A, Toyka KV, Dudel J. Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur. J. Neurosci.10(1), 281–290 (1998).
   PubMedGoogle Scholar
• Buchwald B, Ahangari R, Toyka KV. Differential blocking effects of the monoclonal anti-GQ1b IgM antibody and α-latrotoxin in the absence of complement at the mouse neuromuscular junction. Neurosci. Lett.334(1), 25–28 (2002).
   PubMed Web of Science ®Google Scholar
• Halstead SK, O’Hanlon GM, Humphreys PD et al. Antidisialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain127(9), 2109–2123 (2004).
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Misawa S, Takahashi H et al. Anti-GQ1b antibody does not affect neuromuscular transmission in human limb muscle. J. Neuroimmunol.189(1–2), 158–162 (2007).
   PubMed Web of Science ®Google Scholar
• Hiraga A, Mori M, Ogawara K et al. Recovery patterns and long term prognosis for axonal Guillain–Barré syndrome. J. Neurol. Neurosurg. Psychiatry76(5), 719–722 (2005).
   PubMed Web of Science ®Google Scholar
• Ohtsuka K, Nakamura Y, Hashimoto M et al. Fisher syndrome associated with IgG anti-GQ1b antibody following infection by a specific serotype of Campylobacter jejuni. Ophthalmology105(7), 1281–1285 (1998).
   PubMed Web of Science ®Google Scholar
• Dingle KE, van den Braak N, Colles FM et al. Sequence typing confirms that Campylobacter jejuni strains associated with Guillain–Barré and Miller-Fisher syndromes are of diverse genetic lineage, serotype, and flagella type. J. Clin. Microbiol.39(9), 3346–3349 (2001).
   PubMed Web of Science ®Google Scholar
• Taboada EN, van Belkum A, Yuki N et al. Comparative genomic analysis of Campylobacter jejuni associated with Guillain–Barré and Miller Fisher syndromes: neuropathogenic and enteritis-associated isolates can share high levels of genomic similarity. BMC Genomics8, 359 (2007).
   PubMedGoogle Scholar
• Chiba A, Kusunoki S, Kuwata S, Juji T, Shibata Y, Kanazawa I. HLA and anti-GQ1b IgG antibody in Miller Fisher syndrome and Guillain–Barré syndrome. J. Neuroimmunol.61(1), 85–88 (1995).
   PubMed Web of Science ®Google Scholar
• Koga M, Yuki N, Kashiwase K, Tadokoro K, Juji T, Hirata K. Guillain–Barré and Fisher’s syndromes subsequent to Campylobacter jejuni enteritis are associated with HLA-B54 and Cw1 independent of anti-ganglioside antibodies. J. Neuroimmunol.88(1–2), 62–66 (1998).
   PubMed Web of Science ®Google Scholar
• Susuki K, Nishimoto Y, Yamada M et al. Acute motor axonal neuropathy rabbit model: immune attack on nerve root axons. Ann. Neurol.54(3), 383–388 (2003).
   PubMed Web of Science ®Google Scholar
• Nishimoto Y, Koga M, Kamijo M, Hirata K, Yuki N. Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration. Neurology62(11), 1939–1944 (2004).
   PubMed Web of Science ®Google Scholar
• Halstead SK, Zitman FM, Humphreys PD et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain131(5), 1197–1208 (2008).
   PubMed Web of Science ®Google Scholar
• Halstead SK, Humphreys PD, Zitman FM, Hamer J, Plomp JJ, Willison HJ. C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome. J. Peripher. Nerv. Syst.13(3), 228–235 (2008).
   PubMed Web of Science ®Google Scholar
• Kaida K, Kusunoki S, Kanzaki M, Kamakura K, Motoyoshi K, Kanazawa I. Anti-GQ1b antibody as a factor predictive of mechanical ventilation in Guillain–Barré syndrome. Neurology62(5), 821–824 (2004).
   PubMed Web of Science ®Google Scholar